MacroGenics, Inc. (MGNX) 10-Year Financial Performance & Capital Metrics

MGNX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutMacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Show more

Revenue $148M +159.4%
EBITDA -$103M +35.0%
Net Income -$67M -639.3%
EPS (Diluted) -1.07 -613.3%
Gross Margin 91.71% +7.1%
EBITDA Margin -69.46% +75.0%
Operating Margin -74.54% +74.7%
Net Margin -45.14% -185.0%
ROE -49.85% -710.7%
ROIC -294.58% -79.3%
Debt/Equity 0.32 +45.0%
Interest Coverage -99.17 +15.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 19.1%
✓Trading at only 0.9x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y12.12%

5Y19.05%

3Y25.17%

TTM-10.84%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM22.26%

EPS CAGR

10Y-

5Y-

3Y-

TTM23.57%

ROCE

10Y Avg-43.84%

5Y Avg-56.06%

3Y Avg-55.79%

Latest-49.32%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	100.85M	86.58M	155.52M	60.12M	62.02M	97.76M	75.64M	150.02M	57.19M	148.34M
Revenue Growth %	1.13%	-0.14%	0.8%	-0.61%	0.03%	0.58%	-0.23%	0.98%	-0.62%	1.59%
Cost of Goods Sold+	0	0	0	0	0	0	2.65M	7.38M	8.22M	12.3M
COGS % of Revenue	-	-	-	-	-	-	0.04%	0.05%	0.14%	0.08%
Gross Profit+	100.85M	86.58M	155.52M	60.12M	62.02M	97.76M	72.99M	142.63M	48.97M	136.04M
Gross Margin %	1%	1%	1%	1%	1%	1%	0.96%	0.95%	0.86%	0.92%
Gross Profit Growth %	1.13%	-0.14%	0.8%	-0.61%	0.03%	0.58%	-0.25%	0.95%	-0.66%	1.78%
Operating Expenses+	121.04M	146.62M	177.66M	231.33M	239.21M	228.82M	275.79M	264.05M	217.22M	246.62M
OpEx % of Revenue	1.2%	1.69%	1.14%	3.85%	3.86%	2.34%	3.65%	1.76%	3.8%	1.66%
Selling, General & Admin	22.77M	29.83M	32.65M	40.5M	46.06M	42.74M	63.01M	58.95M	52.19M	71.05M
SG&A % of Revenue	0.23%	0.34%	0.21%	0.67%	0.74%	0.44%	0.83%	0.39%	0.91%	0.48%
Research & Development	98.27M	122.09M	147.23M	190.83M	195.31M	193.2M	214.58M	207.03M	166.58M	177.19M
R&D % of Revenue	0.97%	1.41%	0.95%	3.17%	3.15%	1.98%	2.84%	1.38%	2.91%	1.19%
Other Operating Expenses	42K	1.51M	2.52M	-247K	-2.16M	-7.12M	-1.8M	-1.92M	-1.56M	-1.62M
Operating Income+	-20.18M	-60.04M	-22.14M	-171.21M	-177.19M	-131.06M	-202.79M	-121.42M	-168.24M	-110.58M
Operating Margin %	-0.2%	-0.69%	-0.14%	-2.85%	-2.86%	-1.34%	-2.68%	-0.81%	-2.94%	-0.75%
Operating Income Growth %	0.47%	-1.98%	0.63%	-6.73%	-0.03%	0.26%	-0.55%	0.4%	-0.39%	0.34%
EBITDA+	-17.32M	-52.43M	-14.91M	-162.01M	-164.88M	-119.1M	-191.54M	-109.55M	-158.6M	-103.04M
EBITDA Margin %	-0.17%	-0.61%	-0.1%	-2.69%	-2.66%	-1.22%	-2.53%	-0.73%	-2.77%	-0.69%
EBITDA Growth %	0.53%	-2.03%	0.72%	-9.86%	-0.02%	0.28%	-0.61%	0.43%	-0.45%	0.35%
D&A (Non-Cash Add-back)	2.86M	7.61M	7.23M	9.2M	12.31M	11.96M	11.26M	11.87M	9.64M	7.54M
EBIT	-20.18M	-60.04M	-22.14M	-171.21M	-177.19M	-131.06M	-202.12M	-119.76M	-7.63M	-64.91M
Net Interest Income+	0	0	0	0	3.4M	800K	680K	1.7M	8.26M	8.31M
Interest Income	0	0	0	0	3.4M	800K	680K	1.7M	9.69M	9.42M
Interest Expense	0	0	0	0	0	0	0	0	1.43M	1.11M
Other Income/Expense	42K	1.51M	2.52M	-247K	25.37M	1.32M	680K	1.66M	159.19M	44.56M
Pretax Income+	-20.14M	-58.53M	-19.63M	-171.45M	-151.81M	-129.74M	-202.12M	-119.76M	-9.06M	-66.02M
Pretax Margin %	-0.2%	-0.68%	-0.13%	-2.85%	-2.45%	-1.33%	-2.67%	-0.8%	-0.16%	-0.45%
Income Tax+	0	0	0	-247K	0	0	0	0	0	944K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1.01%
Net Income+	-20.14M	-58.53M	-19.63M	-171.45M	-151.81M	-129.74M	-202.12M	-119.76M	-9.06M	-66.97M
Net Margin %	-0.2%	-0.68%	-0.13%	-2.85%	-2.45%	-1.33%	-2.67%	-0.8%	-0.16%	-0.45%
Net Income Growth %	0.47%	-1.91%	0.66%	-7.74%	0.11%	0.15%	-0.56%	0.41%	0.92%	-6.39%
Net Income (Continuing)	-20.14M	-58.53M	-19.63M	-171.45M	-151.81M	-129.74M	-202.12M	-119.76M	-9.06M	-66.97M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.63	-1.69	-0.54	-4.19	-3.16	-2.25	-3.18	-1.95	-0.15	-1.07
EPS Growth %	0.55%	-1.68%	0.68%	-6.76%	0.25%	0.29%	-0.41%	0.39%	0.92%	-6.13%
EPS (Basic)	-0.63	-1.69	-0.54	-4.19	-3.16	-2.25	-3.18	-1.95	-0.15	-1.07
Diluted Shares Outstanding	31.8M	34.69M	36.1M	40.93M	48.08M	52.44M	59.94M	61.43M	61.93M	62.62M
Basic Shares Outstanding	31.8M	34.69M	36.1M	40.93M	48.08M	52.44M	59.94M	61.41M	61.93M	62.62M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	342.38M	283.95M	322.3M	269.12M	239.78M	312.59M	279.56M	222.18M	251.34M	217.49M
Cash & Short-Term Investments	339.05M	284.98M	305.12M	232.86M	215.76M	272.53M	243.62M	154.35M	229.81M	201.67M
Cash Only	196.17M	84.1M	211.73M	220.13M	126.47M	181.13M	123.47M	108.88M	100.96M	182.84M
Short-Term Investments	142.88M	192.9M	93.39M	12.73M	89.28M	91.4M	120.15M	45.46M	128.85M	18.83M
Accounts Receivable	1.22M	2.76M	13.64M	29.58M	12.74M	23.08M	10.39M	56.22M	10.37M	4.31M
Days Sales Outstanding	4.43	11.65	32.02	179.6	75	86.17	50.12	136.79	66.16	10.6
Inventory	0	-7.99M	0	0	0	0	4.39M	1.45M	1.22M	0
Days Inventory Outstanding	-	-	-	-	-	-	604.16	71.72	54.2	-
Other Current Assets	305K	704K	383K	0	0	0	0	10.16M	9.95M	11.51M
Total Non-Current Assets+	16.89M	27.32M	51.59M	63.01M	72.72M	66.15M	55.69M	67.33M	47.08M	53.06M
Property, Plant & Equipment	14.84M	17.96M	49.98M	56.71M	68.41M	61.52M	54.29M	56.91M	45.69M	42.61M
Fixed Asset Turnover	6.80x	4.82x	3.11x	1.06x	0.91x	1.59x	1.39x	2.64x	1.25x	3.48x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	7.99M	0	0	0	0	0	0	0	0
Other Non-Current Assets	2.04M	1.37M	1.6M	6.29M	4.3M	4.62M	1.4M	1.38M	1.39M	10.46M
Total Assets+	359.27M	311.26M	373.88M	332.13M	312.5M	378.74M	335.25M	289.51M	298.42M	261.65M
Asset Turnover	0.28x	0.28x	0.42x	0.18x	0.20x	0.26x	0.23x	0.52x	0.19x	0.57x
Asset Growth %	1.07%	-0.13%	0.2%	-0.11%	-0.06%	0.21%	-0.11%	-0.14%	0.03%	-0.12%
Total Current Liabilities+	23.29M	27.3M	49.76M	59.94M	45.17M	50.67M	74.58M	48.61M	56.11M	55.53M
Accounts Payable	2.97M	4M	2.45M	4M	4.31M	8.03M	15.5M	4.9M	6.44M	5.01M
Days Payables Outstanding	-	-	-	-	-	-	2.13K	242.16	286.02	148.77
Short-Term Debt	0	0	0	0	0	0	0	4.73M	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	1000K	1000K	1000K
Other Current Liabilities	2.75M	2.91M	1.52M	1.02M	10.7M	4.46M	20.65M	29M	0	0
Current Ratio	14.70x	10.40x	6.48x	4.49x	5.31x	6.17x	3.75x	4.57x	4.48x	3.92x
Quick Ratio	14.70x	10.69x	6.48x	4.49x	5.31x	6.17x	3.69x	4.54x	4.46x	3.92x
Cash Conversion Cycle	-	-	-	-	-	-	-1.48K	-33.65	-165.66	-
Total Non-Current Liabilities+	22.64M	15.21M	24.89M	29.31M	36.71M	32.19M	21.05M	98.89M	89.7M	98.97M
Long-Term Debt	2.69M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	27.55M	25.26M	20.79M	30.11M	30.2M	32.6M
Deferred Tax Liabilities	4.63M	308K	0	0	0	0	0	9.04M	0	8.9M
Other Non-Current Liabilities	7.32M	5.17M	4.05M	10.31M	9.15M	6.93M	258K	258K	258K	1.97M
Total Liabilities	45.93M	42.51M	74.64M	89.25M	81.87M	82.86M	95.63M	147.5M	145.81M	145.6M
Total Debt+	4.71M	1.89M	298K	0	30.57M	29.25M	25.47M	34.83M	33.97M	37.46M
Net Debt	-191.46M	-82.21M	-211.43M	-220.13M	-95.9M	-151.88M	-98M	-74.05M	-66.98M	-145.38M
Debt / Equity	0.02x	0.01x	0.00x	-	0.13x	0.10x	0.11x	0.25x	0.22x	0.32x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-117.65x	-99.17x
Total Equity+	313.34M	268.75M	299.24M	242.88M	230.63M	295.88M	239.62M	142.01M	152.61M	116.06M
Equity Growth %	1.58%	-0.14%	0.11%	-0.19%	-0.05%	0.28%	-0.19%	-0.41%	0.07%	-0.24%
Book Value per Share	9.85	7.75	8.29	5.93	4.80	5.64	4.00	2.31	2.46	1.85
Total Shareholders' Equity	313.34M	268.75M	299.24M	242.88M	230.63M	295.88M	239.62M	142.01M	152.61M	116.06M
Common Stock	343K	349K	369K	424K	490K	562K	613K	617K	621K	628K
Retained Earnings	-234.19M	-292.71M	-312.34M	-490.27M	-642.08M	-771.82M	-973.94M	-1.09B	-1.1B	-1.17B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-5K	-82K	-61K	-3K	16K	-7K	-61K	-5K	-6K	4K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.66M	-43.68M	14.4M	-153.23M	-134.27M	-111.9M	-143.83M	-86.96M	-78.2M	-68.37M
Operating CF Margin %	-0.14%	-0.5%	0.09%	-2.55%	-2.16%	-1.14%	-1.9%	-0.58%	-1.37%	-0.46%
Operating CF Growth %	0.58%	-2.2%	1.33%	-11.64%	0.12%	0.17%	-0.29%	0.4%	0.1%	0.13%
Net Income	-20.14M	-58.53M	-19.63M	-171.45M	-151.81M	-129.74M	-202.12M	-119.76M	-9.06M	-66.97M
Depreciation & Amortization	2.86M	7.61M	7.23M	8.28M	10.85M	11.96M	11.26M	11.87M	9.64M	7.54M
Stock-Based Compensation	7.85M	12.16M	14.74M	16.52M	19.57M	20.68M	23.13M	20.44M	0	29.44M
Deferred Taxes	0	0	0	0	-25.09M	0	0	0	0	0
Other Non-Cash Items	12.36M	26.69M	41.62M	48.39M	25.09M	-260K	6.33M	6.63M	-132.11M	-39.78M
Working Capital Changes	-4.23M	-4.92M	12.06M	-6.58M	-12.88M	-14.53M	17.57M	-6.13M	53.32M	1.39M
Change in Receivables	1.71M	-1.54M	-10.88M	-15.94M	16.84M	-10.34M	12.7M	-45.84M	45.85M	6.06M
Change in Inventory	1.49M	-291K	11.83M	-4.63M	-9.63M	0	-6.42M	55K	230K	-2.19M
Change in Payables	-163K	2.23M	-1.54M	1.55M	787K	3.72M	7.13M	-10.86M	1.28M	-1.53M
Cash from Investing+	-152.11M	-70.25M	77.88M	56.64M	-79.36M	-7.79M	-36.61M	70.72M	-80.08M	149.3M
Capital Expenditures	-9.2M	-11.38M	-29.4M	-24.95M	-4.29M	-5.91M	-6.2M	-3.62M	-1.76M	-3.71M
CapEx % of Revenue	0.09%	0.13%	0.19%	0.42%	0.07%	0.06%	0.08%	0.02%	0.03%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-142.91M	-58.87M	107.28M	81.6M	-75.07M	0	0	0	0	40.16M
Cash from Financing+	204.35M	1.85M	35.35M	104.99M	119.97M	174.34M	122.78M	1.66M	150.36M	960K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	911K	1.89M	1.14M	1.99M	1.31M	3.89M	4.96M	574K	149.35M	960K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-22.86M	-55.06M	-15M	-178.19M	-138.56M	-117.8M	-150.03M	-90.58M	-79.97M	-72.08M
FCF Margin %	-0.23%	-0.64%	-0.1%	-2.96%	-2.23%	-1.2%	-1.98%	-0.6%	-1.4%	-0.49%
FCF Growth %	0.37%	-1.41%	0.73%	-10.88%	0.22%	0.15%	-0.27%	0.4%	0.12%	0.1%
FCF per Share	-0.72	-1.59	-0.42	-4.35	-2.88	-2.25	-2.50	-1.47	-1.29	-1.15
FCF Conversion (FCF/Net Income)	0.68x	0.75x	-0.73x	0.89x	0.88x	0.86x	0.71x	0.73x	8.63x	1.02x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	944K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-9.27%	-20.11%	-6.91%	-63.25%	-64.12%	-49.28%	-75.49%	-62.76%	-6.15%	-49.85%
Return on Invested Capital (ROIC)	-32.35%	-29.2%	-12.11%	-232.28%	-168.77%	-70.53%	-106.5%	-86.9%	-164.31%	-294.58%
Gross Margin	100%	100%	100%	100%	100%	100%	96.5%	95.08%	85.62%	91.71%
Net Margin	-19.97%	-67.6%	-12.62%	-285.18%	-244.76%	-132.71%	-267.2%	-79.83%	-15.84%	-45.14%
Debt / Equity	0.02x	0.01x	0.00x	-	0.13x	0.10x	0.11x	0.25x	0.22x	0.32x
Interest Coverage	-	-	-	-	-	-	-	-	-117.65x	-99.17x
FCF Conversion	0.68x	0.75x	-0.73x	0.89x	0.88x	0.86x	0.71x	0.73x	8.63x	1.02x
Revenue Growth	113.38%	-14.15%	79.62%	-61.34%	3.17%	57.62%	-22.63%	98.32%	-61.88%	159.37%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Revenue From Collaborative Agreements	-	62.02M	97.76M	63.29M	119.3M	28.99M	118.86M
Revenue From Collaborative Agreements Growth	-	-	57.62%	-35.26%	88.49%	-75.70%	309.99%
Product	-	-	-	12.35M	16.73M	17.94M	16.43M
Product Growth	-	-	-	-	35.45%	7.25%	-8.43%
Contract Manufacturing	-	-	-	-	13.99M	9.83M	13.06M
Contract Manufacturing Growth	-	-	-	-	-	-29.70%	32.79%
Revenue From Government Agreements	-	2.16M	7.12M	1.8M	1.92M	1.56M	1.62M
Revenue From Government Agreements Growth	-	-	228.97%	-74.66%	6.60%	-19.08%	4.31%
Revenues From License Agreements	1.3M	-	-	-	-	-	-
Revenues From License Agreements Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

MacroGenics, Inc. (MGNX) reported $126.0M in revenue for fiscal year 2024. This represents a 168% increase from $47.1M in 2011.

MacroGenics, Inc. (MGNX) grew revenue by 159.4% over the past year. This is strong growth.

MacroGenics, Inc. (MGNX) reported a net loss of $75.9M for fiscal year 2024.

Dividend & Returns

MacroGenics, Inc. (MGNX) has a return on equity (ROE) of -49.9%. Negative ROE indicates the company is unprofitable.

MacroGenics, Inc. (MGNX) had negative free cash flow of $164.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

MacroGenics, Inc. (MGNX) 10-Year Financial Performance & Capital Metrics

MGNX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $148M +159.4%
EBITDA -$103M +35.0%
Net Income -$67M -639.3%
EPS (Diluted) -1.07 -613.3%
Gross Margin 91.71% +7.1%
EBITDA Margin -69.46% +75.0%
Operating Margin -74.54% +74.7%
Net Margin -45.14% -185.0%
ROE -49.85% -710.7%
ROIC -294.58% -79.3%
Debt/Equity 0.32 +45.0%
Interest Coverage -99.17 +15.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 19.1%
✓Trading at only 0.9x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y12.12%

5Y19.05%

3Y25.17%

TTM-10.84%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM22.26%

EPS CAGR

10Y-

5Y-

3Y-

TTM23.57%

ROCE

10Y Avg-43.84%

5Y Avg-56.06%

3Y Avg-55.79%

Latest-49.32%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	100.85M	86.58M	155.52M	60.12M	62.02M	97.76M	75.64M	150.02M	57.19M	148.34M
Revenue Growth %	1.13%	-0.14%	0.8%	-0.61%	0.03%	0.58%	-0.23%	0.98%	-0.62%	1.59%
Cost of Goods Sold+	0	0	0	0	0	0	2.65M	7.38M	8.22M	12.3M
COGS % of Revenue	-	-	-	-	-	-	0.04%	0.05%	0.14%	0.08%
Gross Profit+	100.85M	86.58M	155.52M	60.12M	62.02M	97.76M	72.99M	142.63M	48.97M	136.04M
Gross Margin %	1%	1%	1%	1%	1%	1%	0.96%	0.95%	0.86%	0.92%
Gross Profit Growth %	1.13%	-0.14%	0.8%	-0.61%	0.03%	0.58%	-0.25%	0.95%	-0.66%	1.78%
Operating Expenses+	121.04M	146.62M	177.66M	231.33M	239.21M	228.82M	275.79M	264.05M	217.22M	246.62M
OpEx % of Revenue	1.2%	1.69%	1.14%	3.85%	3.86%	2.34%	3.65%	1.76%	3.8%	1.66%
Selling, General & Admin	22.77M	29.83M	32.65M	40.5M	46.06M	42.74M	63.01M	58.95M	52.19M	71.05M
SG&A % of Revenue	0.23%	0.34%	0.21%	0.67%	0.74%	0.44%	0.83%	0.39%	0.91%	0.48%
Research & Development	98.27M	122.09M	147.23M	190.83M	195.31M	193.2M	214.58M	207.03M	166.58M	177.19M
R&D % of Revenue	0.97%	1.41%	0.95%	3.17%	3.15%	1.98%	2.84%	1.38%	2.91%	1.19%
Other Operating Expenses	42K	1.51M	2.52M	-247K	-2.16M	-7.12M	-1.8M	-1.92M	-1.56M	-1.62M
Operating Income+	-20.18M	-60.04M	-22.14M	-171.21M	-177.19M	-131.06M	-202.79M	-121.42M	-168.24M	-110.58M
Operating Margin %	-0.2%	-0.69%	-0.14%	-2.85%	-2.86%	-1.34%	-2.68%	-0.81%	-2.94%	-0.75%
Operating Income Growth %	0.47%	-1.98%	0.63%	-6.73%	-0.03%	0.26%	-0.55%	0.4%	-0.39%	0.34%
EBITDA+	-17.32M	-52.43M	-14.91M	-162.01M	-164.88M	-119.1M	-191.54M	-109.55M	-158.6M	-103.04M
EBITDA Margin %	-0.17%	-0.61%	-0.1%	-2.69%	-2.66%	-1.22%	-2.53%	-0.73%	-2.77%	-0.69%
EBITDA Growth %	0.53%	-2.03%	0.72%	-9.86%	-0.02%	0.28%	-0.61%	0.43%	-0.45%	0.35%
D&A (Non-Cash Add-back)	2.86M	7.61M	7.23M	9.2M	12.31M	11.96M	11.26M	11.87M	9.64M	7.54M
EBIT	-20.18M	-60.04M	-22.14M	-171.21M	-177.19M	-131.06M	-202.12M	-119.76M	-7.63M	-64.91M
Net Interest Income+	0	0	0	0	3.4M	800K	680K	1.7M	8.26M	8.31M
Interest Income	0	0	0	0	3.4M	800K	680K	1.7M	9.69M	9.42M
Interest Expense	0	0	0	0	0	0	0	0	1.43M	1.11M
Other Income/Expense	42K	1.51M	2.52M	-247K	25.37M	1.32M	680K	1.66M	159.19M	44.56M
Pretax Income+	-20.14M	-58.53M	-19.63M	-171.45M	-151.81M	-129.74M	-202.12M	-119.76M	-9.06M	-66.02M
Pretax Margin %	-0.2%	-0.68%	-0.13%	-2.85%	-2.45%	-1.33%	-2.67%	-0.8%	-0.16%	-0.45%
Income Tax+	0	0	0	-247K	0	0	0	0	0	944K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1.01%
Net Income+	-20.14M	-58.53M	-19.63M	-171.45M	-151.81M	-129.74M	-202.12M	-119.76M	-9.06M	-66.97M
Net Margin %	-0.2%	-0.68%	-0.13%	-2.85%	-2.45%	-1.33%	-2.67%	-0.8%	-0.16%	-0.45%
Net Income Growth %	0.47%	-1.91%	0.66%	-7.74%	0.11%	0.15%	-0.56%	0.41%	0.92%	-6.39%
Net Income (Continuing)	-20.14M	-58.53M	-19.63M	-171.45M	-151.81M	-129.74M	-202.12M	-119.76M	-9.06M	-66.97M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.63	-1.69	-0.54	-4.19	-3.16	-2.25	-3.18	-1.95	-0.15	-1.07
EPS Growth %	0.55%	-1.68%	0.68%	-6.76%	0.25%	0.29%	-0.41%	0.39%	0.92%	-6.13%
EPS (Basic)	-0.63	-1.69	-0.54	-4.19	-3.16	-2.25	-3.18	-1.95	-0.15	-1.07
Diluted Shares Outstanding	31.8M	34.69M	36.1M	40.93M	48.08M	52.44M	59.94M	61.43M	61.93M	62.62M
Basic Shares Outstanding	31.8M	34.69M	36.1M	40.93M	48.08M	52.44M	59.94M	61.41M	61.93M	62.62M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	342.38M	283.95M	322.3M	269.12M	239.78M	312.59M	279.56M	222.18M	251.34M	217.49M
Cash & Short-Term Investments	339.05M	284.98M	305.12M	232.86M	215.76M	272.53M	243.62M	154.35M	229.81M	201.67M
Cash Only	196.17M	84.1M	211.73M	220.13M	126.47M	181.13M	123.47M	108.88M	100.96M	182.84M
Short-Term Investments	142.88M	192.9M	93.39M	12.73M	89.28M	91.4M	120.15M	45.46M	128.85M	18.83M
Accounts Receivable	1.22M	2.76M	13.64M	29.58M	12.74M	23.08M	10.39M	56.22M	10.37M	4.31M
Days Sales Outstanding	4.43	11.65	32.02	179.6	75	86.17	50.12	136.79	66.16	10.6
Inventory	0	-7.99M	0	0	0	0	4.39M	1.45M	1.22M	0
Days Inventory Outstanding	-	-	-	-	-	-	604.16	71.72	54.2	-
Other Current Assets	305K	704K	383K	0	0	0	0	10.16M	9.95M	11.51M
Total Non-Current Assets+	16.89M	27.32M	51.59M	63.01M	72.72M	66.15M	55.69M	67.33M	47.08M	53.06M
Property, Plant & Equipment	14.84M	17.96M	49.98M	56.71M	68.41M	61.52M	54.29M	56.91M	45.69M	42.61M
Fixed Asset Turnover	6.80x	4.82x	3.11x	1.06x	0.91x	1.59x	1.39x	2.64x	1.25x	3.48x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	7.99M	0	0	0	0	0	0	0	0
Other Non-Current Assets	2.04M	1.37M	1.6M	6.29M	4.3M	4.62M	1.4M	1.38M	1.39M	10.46M
Total Assets+	359.27M	311.26M	373.88M	332.13M	312.5M	378.74M	335.25M	289.51M	298.42M	261.65M
Asset Turnover	0.28x	0.28x	0.42x	0.18x	0.20x	0.26x	0.23x	0.52x	0.19x	0.57x
Asset Growth %	1.07%	-0.13%	0.2%	-0.11%	-0.06%	0.21%	-0.11%	-0.14%	0.03%	-0.12%
Total Current Liabilities+	23.29M	27.3M	49.76M	59.94M	45.17M	50.67M	74.58M	48.61M	56.11M	55.53M
Accounts Payable	2.97M	4M	2.45M	4M	4.31M	8.03M	15.5M	4.9M	6.44M	5.01M
Days Payables Outstanding	-	-	-	-	-	-	2.13K	242.16	286.02	148.77
Short-Term Debt	0	0	0	0	0	0	0	4.73M	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	1000K	1000K	1000K
Other Current Liabilities	2.75M	2.91M	1.52M	1.02M	10.7M	4.46M	20.65M	29M	0	0
Current Ratio	14.70x	10.40x	6.48x	4.49x	5.31x	6.17x	3.75x	4.57x	4.48x	3.92x
Quick Ratio	14.70x	10.69x	6.48x	4.49x	5.31x	6.17x	3.69x	4.54x	4.46x	3.92x
Cash Conversion Cycle	-	-	-	-	-	-	-1.48K	-33.65	-165.66	-
Total Non-Current Liabilities+	22.64M	15.21M	24.89M	29.31M	36.71M	32.19M	21.05M	98.89M	89.7M	98.97M
Long-Term Debt	2.69M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	27.55M	25.26M	20.79M	30.11M	30.2M	32.6M
Deferred Tax Liabilities	4.63M	308K	0	0	0	0	0	9.04M	0	8.9M
Other Non-Current Liabilities	7.32M	5.17M	4.05M	10.31M	9.15M	6.93M	258K	258K	258K	1.97M
Total Liabilities	45.93M	42.51M	74.64M	89.25M	81.87M	82.86M	95.63M	147.5M	145.81M	145.6M
Total Debt+	4.71M	1.89M	298K	0	30.57M	29.25M	25.47M	34.83M	33.97M	37.46M
Net Debt	-191.46M	-82.21M	-211.43M	-220.13M	-95.9M	-151.88M	-98M	-74.05M	-66.98M	-145.38M
Debt / Equity	0.02x	0.01x	0.00x	-	0.13x	0.10x	0.11x	0.25x	0.22x	0.32x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-117.65x	-99.17x
Total Equity+	313.34M	268.75M	299.24M	242.88M	230.63M	295.88M	239.62M	142.01M	152.61M	116.06M
Equity Growth %	1.58%	-0.14%	0.11%	-0.19%	-0.05%	0.28%	-0.19%	-0.41%	0.07%	-0.24%
Book Value per Share	9.85	7.75	8.29	5.93	4.80	5.64	4.00	2.31	2.46	1.85
Total Shareholders' Equity	313.34M	268.75M	299.24M	242.88M	230.63M	295.88M	239.62M	142.01M	152.61M	116.06M
Common Stock	343K	349K	369K	424K	490K	562K	613K	617K	621K	628K
Retained Earnings	-234.19M	-292.71M	-312.34M	-490.27M	-642.08M	-771.82M	-973.94M	-1.09B	-1.1B	-1.17B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-5K	-82K	-61K	-3K	16K	-7K	-61K	-5K	-6K	4K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.66M	-43.68M	14.4M	-153.23M	-134.27M	-111.9M	-143.83M	-86.96M	-78.2M	-68.37M
Operating CF Margin %	-0.14%	-0.5%	0.09%	-2.55%	-2.16%	-1.14%	-1.9%	-0.58%	-1.37%	-0.46%
Operating CF Growth %	0.58%	-2.2%	1.33%	-11.64%	0.12%	0.17%	-0.29%	0.4%	0.1%	0.13%
Net Income	-20.14M	-58.53M	-19.63M	-171.45M	-151.81M	-129.74M	-202.12M	-119.76M	-9.06M	-66.97M
Depreciation & Amortization	2.86M	7.61M	7.23M	8.28M	10.85M	11.96M	11.26M	11.87M	9.64M	7.54M
Stock-Based Compensation	7.85M	12.16M	14.74M	16.52M	19.57M	20.68M	23.13M	20.44M	0	29.44M
Deferred Taxes	0	0	0	0	-25.09M	0	0	0	0	0
Other Non-Cash Items	12.36M	26.69M	41.62M	48.39M	25.09M	-260K	6.33M	6.63M	-132.11M	-39.78M
Working Capital Changes	-4.23M	-4.92M	12.06M	-6.58M	-12.88M	-14.53M	17.57M	-6.13M	53.32M	1.39M
Change in Receivables	1.71M	-1.54M	-10.88M	-15.94M	16.84M	-10.34M	12.7M	-45.84M	45.85M	6.06M
Change in Inventory	1.49M	-291K	11.83M	-4.63M	-9.63M	0	-6.42M	55K	230K	-2.19M
Change in Payables	-163K	2.23M	-1.54M	1.55M	787K	3.72M	7.13M	-10.86M	1.28M	-1.53M
Cash from Investing+	-152.11M	-70.25M	77.88M	56.64M	-79.36M	-7.79M	-36.61M	70.72M	-80.08M	149.3M
Capital Expenditures	-9.2M	-11.38M	-29.4M	-24.95M	-4.29M	-5.91M	-6.2M	-3.62M	-1.76M	-3.71M
CapEx % of Revenue	0.09%	0.13%	0.19%	0.42%	0.07%	0.06%	0.08%	0.02%	0.03%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-142.91M	-58.87M	107.28M	81.6M	-75.07M	0	0	0	0	40.16M
Cash from Financing+	204.35M	1.85M	35.35M	104.99M	119.97M	174.34M	122.78M	1.66M	150.36M	960K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	911K	1.89M	1.14M	1.99M	1.31M	3.89M	4.96M	574K	149.35M	960K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-22.86M	-55.06M	-15M	-178.19M	-138.56M	-117.8M	-150.03M	-90.58M	-79.97M	-72.08M
FCF Margin %	-0.23%	-0.64%	-0.1%	-2.96%	-2.23%	-1.2%	-1.98%	-0.6%	-1.4%	-0.49%
FCF Growth %	0.37%	-1.41%	0.73%	-10.88%	0.22%	0.15%	-0.27%	0.4%	0.12%	0.1%
FCF per Share	-0.72	-1.59	-0.42	-4.35	-2.88	-2.25	-2.50	-1.47	-1.29	-1.15
FCF Conversion (FCF/Net Income)	0.68x	0.75x	-0.73x	0.89x	0.88x	0.86x	0.71x	0.73x	8.63x	1.02x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	944K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-9.27%	-20.11%	-6.91%	-63.25%	-64.12%	-49.28%	-75.49%	-62.76%	-6.15%	-49.85%
Return on Invested Capital (ROIC)	-32.35%	-29.2%	-12.11%	-232.28%	-168.77%	-70.53%	-106.5%	-86.9%	-164.31%	-294.58%
Gross Margin	100%	100%	100%	100%	100%	100%	96.5%	95.08%	85.62%	91.71%
Net Margin	-19.97%	-67.6%	-12.62%	-285.18%	-244.76%	-132.71%	-267.2%	-79.83%	-15.84%	-45.14%
Debt / Equity	0.02x	0.01x	0.00x	-	0.13x	0.10x	0.11x	0.25x	0.22x	0.32x
Interest Coverage	-	-	-	-	-	-	-	-	-117.65x	-99.17x
FCF Conversion	0.68x	0.75x	-0.73x	0.89x	0.88x	0.86x	0.71x	0.73x	8.63x	1.02x
Revenue Growth	113.38%	-14.15%	79.62%	-61.34%	3.17%	57.62%	-22.63%	98.32%	-61.88%	159.37%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Revenue From Collaborative Agreements	-	62.02M	97.76M	63.29M	119.3M	28.99M	118.86M
Revenue From Collaborative Agreements Growth	-	-	57.62%	-35.26%	88.49%	-75.70%	309.99%
Product	-	-	-	12.35M	16.73M	17.94M	16.43M
Product Growth	-	-	-	-	35.45%	7.25%	-8.43%
Contract Manufacturing	-	-	-	-	13.99M	9.83M	13.06M
Contract Manufacturing Growth	-	-	-	-	-	-29.70%	32.79%
Revenue From Government Agreements	-	2.16M	7.12M	1.8M	1.92M	1.56M	1.62M
Revenue From Government Agreements Growth	-	-	228.97%	-74.66%	6.60%	-19.08%	4.31%
Revenues From License Agreements	1.3M	-	-	-	-	-	-
Revenues From License Agreements Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

MacroGenics, Inc. (MGNX) reported $126.0M in revenue for fiscal year 2024. This represents a 168% increase from $47.1M in 2011.

MacroGenics, Inc. (MGNX) grew revenue by 159.4% over the past year. This is strong growth.

MacroGenics, Inc. (MGNX) reported a net loss of $75.9M for fiscal year 2024.

Dividend & Returns

MacroGenics, Inc. (MGNX) has a return on equity (ROE) of -49.9%. Negative ROE indicates the company is unprofitable.

MacroGenics, Inc. (MGNX) had negative free cash flow of $164.8M in fiscal year 2024, likely due to heavy capital investments.